Department of Urology, Third Hospital of Peking University, Beijing 100191, China.
Chin Med J (Engl). 2011 Jan;124(2):205-9.
Simultaneous pancreas-kidney transplantation (SPKT) frees the diabetic patient with end-stage nephropathy from dialysis and daily insulin injections. Herein, we review consecutive cases of SPKT with bladder drainage performed at our institution over an 8-year period.
The study population included 21 patients (16 males and 5 females) who underwent SPKT between September 2001 and September 2009. Seven patients had type-1 diabetes and 14 had type-2 diabetes. Nineteen patients were on dialysis at the time of transplantation. Donation after cardiac death donors were selected for SPKT. The mean human leukocyte antigen match was 2 (range 0 - 4). SPKT was always performed using bladder drainage and vascular anastomoses to the systemic circulation. Immunosuppressive treatment consisted of anti-lymphocyte globulin induction followed by tacrolimus, mycophenolate mofetil, and prednisone.
The mean hospital stay was 45.43 days. After a mean follow-up of 39.4 months, survival rates for patient, kidney, and pancreas were 76.2%, 76.2%, and 66.7% at 1 year; 76.2%, 59.3%, and 55.6% at 5 years; and 57.1%, 39.5%, and 41.7% at 8 years, respectively. Major complications included anastomotic leaks, reflux pancreatitis, and rejection. Six patients died from septic shock (n = 3), duodenal stump leak (1), cardiac arrest (1), or renal failure (1). Eight kidney grafts were lost due to acute rejection (n = 2), chronic rejection (3), and death with a functioning graft (3). Pancreatic graft failure (9) was caused by thrombosis (n = 1), rejection (2), duodenal stump leak (1), and death with a functioning graft (5).
SPKT is a valid therapeutic option for uremic diabetics although few hospitals in China can undertake SPKT.
胰肾联合移植(SPKT)使终末期肾病合并糖尿病的患者免于透析和每日胰岛素注射。在此,我们回顾了在我院进行的连续 8 年的 SPKT 伴膀胱引流病例。
研究人群包括 21 例患者(男 16 例,女 5 例),于 2001 年 9 月至 2009 年 9 月期间行 SPKT。7 例为 1 型糖尿病,14 例为 2 型糖尿病。19 例患者在移植时已行透析。选择心脏死亡后供者进行 SPKT。平均人类白细胞抗原匹配为 2(0-4)。SPKT 始终采用膀胱引流和与体循环的血管吻合。免疫抑制治疗包括抗淋巴细胞球蛋白诱导,随后使用他克莫司、霉酚酸酯和泼尼松。
平均住院时间为 45.43 天。平均随访 39.4 个月后,患者、肾脏和胰腺的 1 年生存率分别为 76.2%、76.2%和 66.7%;5 年生存率分别为 76.2%、59.3%和 55.6%;8 年生存率分别为 57.1%、39.5%和 41.7%。主要并发症包括吻合口漏、反流性胰腺炎和排斥反应。6 例患者死于感染性休克(n=3)、十二指肠残端漏(1)、心脏骤停(1)或肾衰竭(1)。8 例肾脏移植物丢失,原因分别为急性排斥反应(n=2)、慢性排斥反应(3)和带功能移植物死亡(3)。9 例胰腺移植物失功的原因分别为血栓形成(n=1)、排斥反应(2)、十二指肠残端漏(1)和带功能移植物死亡(5)。
尽管中国只有少数医院能够进行 SPKT,但 SPKT 是尿毒症合并糖尿病患者的一种有效治疗选择。